Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021

Rhea-AI Summary

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) announced that CEO Brian Markison and COO James Schaub will present at the H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021. The presentation will be available on demand and archived for 30 days on the Company’s website. Osmotica focuses on developing specialty products for underserved markets, with subsidiaries including RVL Pharmaceuticals for ophthalmic products. The Company operates in the U.S. and Hungary.

BRIDGEWATER, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James “JD” Schaub, Chief Operating Officer, will present at the H.C. Wainwright Ophthalmology Virtual Conference as follows:

Date:	Tuesday, August 17, 2021
Time:	On Demand
Webcast:	https://journey.ct.events/view/b4009ee7-d4bf-41a2-b263-30a028b27c98

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.osmotica.com under the “Investor & News” section.

About Osmotica Pharmaceuticals plc

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting UPNEEQ^®. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations.

Osmotica has operations in the United States and Hungary.

Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

FAQ

When will Osmotica Pharmaceuticals present at H.C. Wainwright Ophthalmology Virtual Conference?

Osmotica Pharmaceuticals will present on August 17, 2021.

Who will present for Osmotica Pharmaceuticals at the conference?

CEO Brian Markison and COO James Schaub will present for Osmotica Pharmaceuticals.

How can I access the Osmotica Pharmaceuticals presentation?

The presentation will be available on demand and archived for 30 days on Osmotica's website.

What is the focus of Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals focuses on developing specialty products for underserved patient populations.

Is Osmotica Pharmaceuticals involved in ophthalmic products?

Yes, Osmotica's subsidiary RVL Pharmaceuticals supports the ophthalmic product UPNEEQ®.